ACC Rockies Chapter Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.


For more information and to register, please visit: ACC Rockies Chapter Meeting 2026



Alina Robert, MD, FACC Chapter President

Robert Duerr, MD, FACC Incoming Governor

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS feed: Latest in Cardiology from ACC.org Latest in Cardiology from ACC.org

  • Is TTE-Guided Permanent Pacemaker Implantation Feasible Without Fluoroscopy?
    Transthoracic echocardiography (TTE)-guided permanent pacemaker implantation without fluoroscopy was feasible in patients with adequate supine acoustic windows, according to a prospective, single-center study recently published in JACC: Advances.
  • Black Adults in Disadvantaged Neighborhoods Less Likely to Be Diagnosed With AFib
    Among individuals living in more disadvantaged neighborhoods, non-Hispanic Black adults were less likely to be diagnosed with atrial fibrillation (AFib) than non-Hispanic White adults, according to a cohort study of Medicare Advantage and commercially insured individuals published Oct. 23 in JAMA Network Open.
  • Can Echocardiographic Evaluation of Severe MR Be More Efficient?
    Certain criteria from the American Society of Echocardiography (ASE) guidelines, such as pulmonary vein systolic reversal and left ventricle (LV) remodeling parameters, are "highly specific" for diagnosing severe mitral regurgitation (MR) even when less than four criteria are present, according to a recent study published in JACC: Cardiovascular Imaging.
  • Frailty and Sarcopenia in HFpEF: Considerations for GLP1RAs
    Heart failure with preserved ejection fraction (HFpEF) affects an estimated 3 million people in the United States and up to 32 million worldwide, with an estimated lifetime risk of heart failure (HF) exceeding 10% at 45 years of age in both men and women.
  • CAUGHT-CAD Analysis: Statin Therapy and Plaque Passivation
    Statin treatment in asymptomatic, intermediate-risk individuals was associated with plaque passivation, a shift toward higher density calcium within coronary plaques, with greater increases in high- and very high-density calcium among patients achieving an LDL-C reduction ≥30%...